NCT04055220 2026-02-17
REGOSTA
Centre Leon Berard
Phase NA Recruiting
Clinical Trials
8 trialsNCT07115550 2025-08-11
A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma
Huai'an First People's Hospital
Phase NA Not yet recruiting
NCT06456515 2025-02-17
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
The First People's Hospital of Changzhou
Phase NA Recruiting
NCT02175095 2024-10-04
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Asan Medical Center
Phase NA Completed
NCT05818267 2023-07-14
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
Changhai Hospital
Phase NA Unknown
NCT05233358 2022-02-10
HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure
The Central Hospital of Lishui City
Phase NA Unknown
NCT01996969 2019-02-22
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
Seoul National University Hospital
Phase NA Completed
NCT03698253 2018-10-05
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase NA Completed